OCUL

Ocular Therapeut

• Reuters·04/01 11:03

  Ocular Therapeutix to present additional SOL-1 Phase 3 AXPAXLI wet AMD data in April

• TipRanks·03/31 18:00

  Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Ocular Therapeutix (OCUL)

• TipRanks·03/27 10:40

  Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Rhythm Pharmaceuticals (RYTM)

• Seeking Alpha·03/21 14:23

  EyePoint sues Ocular over claims related to lead asset

• Benzinga·03/20 20:39

  EyePoint Files Lawsuit Against Ocular Therapeutix Alleging Defamation And Misleading Claims Over DURAVYU Clinical Results

• Reuters·03/20 20:34

  EyePoint sues Ocular Therapeutix over alleged false statements about DURAVYU clinical results

• Seeking Alpha·03/19 18:37

  Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech

• Reuters·03/09 20:01

  Ocular Therapeutix grants inducement equity awards covering 60,175 stock options and 19,975 RSUs

• Reuters·03/09 20:01

  OCULAR THERAPEUTIX™ REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• Seeking Alpha·03/05 11:08

  EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check

• Benzinga·03/03 13:37

  GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday

• TipRanks·03/03 11:45

  Ocular Therapeutix price target raised to $27 from $24 at BofA

• TipRanks·03/03 11:15

  OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target

• Dow Jones·03/03 10:16

  Ocular Therapeutix Is Maintained at Buy by Clear Street

• Dow Jones·03/03 10:16

  Ocular Therapeutix Price Target Raised to $28.00/Share From $21.00 by Clear Street